Klein, Sebastian http://orcid.org/0000-0002-2188-9377
Wuerdemann, Nora
Demers, Imke http://orcid.org/0000-0001-9531-8414
Kopp, Christopher
Quantius, Jennifer
Charpentier, Arthur
Tolkach, Yuri
Brinker, Klaus
Sharma, Shachi Jenny
George, Julie
Hess, Jochen
Stögbauer, Fabian http://orcid.org/0000-0002-8897-5165
Lacko, Martin http://orcid.org/0000-0003-2868-4822
Struijlaart, Marijn
van den Hout, Mari F.C.M.
Wagner, Steffen http://orcid.org/0000-0003-0873-1601
Wittekindt, Claus
Langer, Christine
Arens, Christoph http://orcid.org/0000-0001-8072-1438
Buettner, Reinhard http://orcid.org/0000-0001-8806-4786
Quaas, Alexander
Reinhardt, Hans Christian
Speel, Ernst-Jan
Klussmann, Jens Peter
Article History
Received: 31 August 2022
Accepted: 10 August 2023
First Online: 19 August 2023
Competing interests
: J.H. received consulting and lecture fees from BMS, also received research funding from CureVac. R.B. received consulting and lecture fees from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Illumina, Lilly, Merck-Serono, MSD, Novartis, Qiagen, Pfizer, Roche, Targos MP Inc. R.B. is Co-Founder and Scientific Advisor for Targos Mol. Pathology Inc and member of the Directory Board Gnothis Inc. H.C.R. received consulting and lecture fees from Novartis, Abbvie, AstraZeneca, Vertex and Merck. H.C.R. received research funding from AstraZeneca and Gilead Pharmaceuticals. HCR is a co-founder of CDL Therapeutics GmbH. The remaining authors declare no competing interests.